Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis Journal Article
| Authors: | Torka, P.; Pederson, L. D.; Knopp, M. V.; Poon, D.; Zhang, J.; Kahl, B. S.; Higley, H. R.; Kelloff, G.; Friedberg, J. W.; Schwartz, L. H.; Wilson, W. H.; Leonard, J. P.; Bartlett, N. L.; Schöder, H.; Ruppert, A. S. |
| Article Title: | Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis |
| Abstract: | Background: Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5-point scale (5-PS). Methods: In CALGB 50303, patients with DLBCL received frontline R-CHOP or DA-EPOCH-R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5-PS with progression-free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. In this patient cohort, we retrospectively compared local vs central iPET readings and evaluated associations between local imaging data and survival outcomes. Results: Agreement between local and central review was moderate (kappa = 0.53) for VSS and high (kappa = 0.81) for ∆SUV categories (<66% vs. ≥66%). ∆SUV ≥66% at iPET was significantly associated with PFS (p = 0.03) and OS (p = 0.002), but VSS was not. Associations with PFS/OS when applying local review vs central review were comparable. Conclusions: These data suggest that local PET interpretation for response determination may be acceptable in clinical trials. Our findings also highlight limitations of VSS and call for incorporation of more objective measures of response assessment in clinical trials. © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. |
| Keywords: | cancer survival; disease-free survival; retrospective studies; major clinical study; overall survival; prednisone; doxorubicin; cancer patient; disease free survival; rituximab; positron emission tomography; progression free survival; multiple cycle treatment; etoposide; cyclophosphamide; diagnostic imaging; retrospective study; vincristine sulfate; fluorodeoxyglucose f 18; fluorodeoxyglucose f18; positron-emission tomography; lymphoma, large b-cell, diffuse; procedures; diffuse large b cell lymphoma; humans; prognosis; human; article; evaluation study; interim pet; deauville 5-ps; international harmonization project criteria; visual scoring system; δsuv |
| Journal Title: | Cancer Medicine |
| Volume: | 12 |
| Issue: | 7 |
| ISSN: | 2045-7634 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-04-01 |
| Start Page: | 8211 |
| End Page: | 8217 |
| Language: | English |
| DOI: | 10.1002/cam4.5628 |
| PUBMED: | 36799072 |
| PROVIDER: | scopus |
| PMCID: | PMC10134372 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus |
